Swan Capital’s ARK Genomic Revolution ETF ARKG Stock Holding History

Swan Capital’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$847	Hold	20	–	–	﹤0.01%	477
2026 Q1	$532	Hold	20	–	–	﹤0.01%	489
2025 Q4	$584	Buy	+20	New	+$600	﹤0.01%	442

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Swan Capital's ARKG Position: Q2 2026 in Review

Swan Capital held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 20 shares worth $847. The position accounts for ﹤0.01% of the portfolio, ranked #477.

Swan Capital first reported a position in ARKG in Q4 2025 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Swan Capital held 20 shares of ARK Genomic Revolution ETF worth $847 as of Q2 2026.
Swan Capital left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of Swan Capital's portfolio in Q2 2026, its #477 holding.
Swan Capital first reported a position in ARK Genomic Revolution ETF in Q4 2025 and has held it in 3 quarters since.
272 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Swan Capital's 13F filing for Q2 2026, filed 13 Aug 2026.